XML 35 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity Method Accounting for Common Stock of OncoCyte, at fair value (Tables)
 9 Months Ended
Sep. 30, 2017
OncoCyte [Member]  
Schedule of Equity Method Investments [Line Items]  
Unaudited results of operations
The unaudited condensed results of operations for the three and nine months ended September 30, 2017 and 2016 and for the period January 1, 2017 to February 16, 2017 are summarized below (in thousands):

 
 
Three Months Ended
September 30,
 
 
Nine Months Ended
September 30,
 
 
For the Period
January 1, 2017 to
February 16, 2017
 
 
 
2017
 
2016
 
2017
 
2016
   
Condensed Statements of Operations (unaudited) (1):
                    
Research and development expense
 
$
1,836
  
$
1,363
  
$
5,667
  
$
4,246
  
$
798
 
General and administrative expense
  
4,289
   
1,063
   
7,447
   
3,145
   
377
 
Sales and marketing expense
  
710
   
156
   
1,843
   
655
   
213
 
Loss from operations
  
(6,835
)
  
(2,582
)
  
(14,957
)
  
(8,046
)
  
(1,388
)
Net loss
 
$
(6,906
)
 
$
(2,595
)
 
$
(15,415
)
 
$
(8,065
)
 
$
(1,392
)

(1) The condensed unaudited statements of operations information included in the table above for the period January 1, 2017 through February 16, 2017, and for the three and nine months ended September 30, 2016, reflects OncoCyte results of operations included in BioTime's condensed consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016, as applicable, respectively, after intercompany eliminations. The information for OncoCyte for the period from February 17, 2017 through September 30, 2017 is not included in BioTime's condensed consolidated statements of operations for the three and nine months ended September 30, 2017, due to the OncoCyte Deconsolidation on February 17, 2017.